icon-folder.gif   Conference Reports for NATAP  
  HIV Glasgow
23-26 October 2016
Glasgow, UK
Back grey_arrow_rt.gif
48 Week Results from two studies: Switching to RPV/FTC/TAF from
EFV/FTC/TDF (Study 1160) or RPV/FTC/TDF (Study 1216)

  Reported by Jules Levin
HIV Glasgow 2016 Oct 23-26 [in sunny Glasgow:) ]
Chloe Orkin,1 Edwin DeJesus,2 Moti Ramgopal,3 Gordon Crofoot,4 Peter Ruane,5 Anthony LaMarca,6 Anthony Mills,7 Bernard Vandercam,8 Joseph De Wet,9 Jurgen Rockstroh,10 Adriano Lazzarin,11 Bart Rijnders,12 Daniel Podzamczer,13 Anders Thalme,14 Marcel Stoeckle,15 Danielle Porter,16 Hui Liu,16 Andrew Cheng,16 Erin Quirk,16 Devi SenGupta,16 Huyen Cao16
1Royal London Hospital, London, UK; 2Orlando Immunology Center, Orlando, Florida, USA; 3Midway Immunology and Research Center, Fort Pierce, Florida, USA; 4The Crofoot Research Center, Houston, Texas, USA; 5Ruane Medical & Liver Health Institute, Los Angeles, California, USA; 6Therafirst Medical Centers, Fort Lauderdale, Florida, USA; 7Southern California Men's Medical Group, Los Angeles, California, USA; 8Cliniques Universitaires Saint-Luc, Brussels, Belgium; 9Spectrum Health Care, Vancouver, British Columbia, Canada; 10Universitätsklinikum Bonn, Germany; 11Ospedale San Raffaele, Milano, Italy; 12Erasmus University Medical Center, Rotterdam, the Netherlands; 13Hospital Universitari de Bellvitge, Barcelona, Spain; 14Karolinska Universitetssjukhuset, Solna, Sweden; 15Universitätsspital Basel, Switzerland; 16Gilead Sciences, Inc., Foster City, California, USA    







Patients with GERD or esophagitis discontinued to initiate or resume PPI treatment Fractures - multiple due to motor vehicle accident
eGFR decreased :
74-year old male participant in the RPV/FTC/TAF group discontinued the study drug due to a decreased CrCl without evidence of proteinuria or glycosuria. This patient had a prior history of hypertension and screening CrCl of 54.2mL/ min. The adverse event was considered related to study drug, with the lowest CrCl being 26.4mL/min. Study drug was discontinued and the patient initiated non-study drug treatment with another TAF-containing single-tablet regimen (elvitegravir/cobicistat/FTC/TAF). CrCl returned to baseline (51·7 mL/min) after 4 weeks.